(19) United States (12) Patent Application Publication (10) Pub
Total Page:16
File Type:pdf, Size:1020Kb
US 20140234454A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2014/0234454 A1 ASIEDU et al. (43) Pub. Date: Aug. 21, 2014 (54) COMPOSITION FOR TREATING AIDS AND Publication Classi?cation ASSOCIATED CONDITIONS (51) Int. Cl. (71) Applicant: WILFRED-RAMIX, INC., A61K 36/185 (2006.01) Bridgewater, NJ (US) A61K 36/888 (2006.01) A61K36/22 (2006.01) (72) Inventors: William ASIEDU, Accra (GH); (52) us CL Frederick Asiedu, Accra (GH); Manny CPC ............. .. A61K 36/185 (2013.01); A61K 36/22 Elwin, Accra (GH); Michael Nsiah (2013.01); A61K 36/888 (2013.01) DouduACCIa (GH); CharlesAntwi USPC ........................................................ .. 424/769 Boateng, Accra (GH); Kwasi Appiah-Kubi, Accra (GH); Seth Opoku (57) ABSTRACT Ware, Accra (GH); Debrah Boateng, An Aids and associated conditions related to Aids treating Accra (GH); Ko? Ampim, Accra (GH); compositions is disclosed. The compositions comprise: a William Owusu, Accra (GH); Akwete medicament selected from an extract of at least one of the Lex Adjei, Bridgewater, NJ (U S) following plant families; Apocynaceae (Pleioscarpa Bicar pellata); Annonaceae (Cleistopholis Patens); Dichapetal (73) Assignee: WILFRED-RAMIX,INC., aceae (Dichapetehan Madagasca Riense); Annoceae (Uvaris Bridgewater, NJ (US) trum Pierreanum); Cynocynaceae (Strophantus Gratus); Asclepiadaceae (Gongronema Latifolium); Combretaceae (21) App1.No.: 14/261,171 (Combretum Racemosum); Apocynaceae (Alostonia Boonei); Amaranthaceae (Alternanthera Pungens); Aroceae (22) Filed: Apr. 24, 2014 (Anchomanes Differmis); Cyperaceae (Seleria Voivinil); Anacardiaceae (Lannea Acida); Bignoniaceae (Kigelia Afri cana); Bombacaceae (Ceiba Pentanota); Anarcardiaceae Related US. Application Data (Antrocaryon Micraster); Bombacaceae (Bombax Bounopo (60) Division of application No. 13/949,613, ?led on Jul. zense); Anarcardiaceae (Spondias Mombin); Caricaceae 24, 2013, now Pat. No. 8,771,763, Which is a division (Carica Papaya); a glyceryl ester of any of the foregoing of application No. 12/828,956, ?led on Jul. 1, 2010, extracts; a saponin of any of the foregoing extracts; an alka nOW abandoned, Which is a continuation of application loid of any of the foregoing extracts; a protein of any of the No. 10/902,993, ?led on Jul. 30, 2004, nOW Pat. No. foregoing extracts; a fat of any of the foregoing extracts; a 7,749,544, Which is a continuation of application No. sugar of any of the foregoing extracts; and any mixture of any 10/241,973, ?led on Sep. 12, 2002, nOW abandoned. of the foregoing. US 2014/0234454 A1 Aug. 21,2014 COMPOSITION FOR TREATING AIDS AND tional serious conditions in the syndrome, as well as to further ASSOCIATED CONDITIONS improve the speci?city of the de?nition used for reporting cases. CROSS REFERENCE TO RELATED [0007] The current case de?nition of AIDS has provided APPLICATIONS useful data on disease trends, because it is precise, consis tently interpreted, and highly speci?c. Other manifestations [0001] The present application is a Divisional of copending of HTLV-III/ LAV infections than those currently proposed to US. patent application Ser. No. 12/828,956, ?led Jul. 1,2010, be reported are less speci?c and less likely to be consistently which is a Continuation of US. patent application Ser. No. reported nationally. Milder disease associated with HTLV-III/ 10/902,993, ?led Jul. 30, 2004, now US. Pat. No. 7,749,544, LAV infections and asymptomatic infections may be report issued Jul. 6, 2010, which is a Continuation of U,S. patent able in some states and cities but will not be nationally report application Ser. No. 10/241,973, ?led Sep. 12, 2002, now able. Because persons with less speci?c or milder abandoned; all of the foregoing applications are incorporated manifestations of HTLV-III/LAV infection may be important herein by reference in their entireties. in transmitting the virus, estimates of the number of such persons are of value. These estimates can be obtained through BACKGROUND OF THE INVENTION epidemiologic studies or special surveys in speci?c popula tions. [0002] 1. Field of the Invention [0008] Issues related to the case de?nition of AIDS were discussed by the Conference of State and Territorial Epide [0003] This invention relates to a composition for treating miologists (CSTE) at its annual meeting in Madison, Wis., AIDS and related conditions, and more particular, to a com June 2-5, 1985. The CSTE approved the following resolu position comprising at least one extract of a selected plant. tions [0004] 2. Description of the PriorArt [0009] 1. that the ease de?nition of AIDS used for [0005] Patients with illnesses that, in retrospect, were national reporting continue to include only the more manifestations of acquired immunode?ciency syndrome severe manifestations of HTLV-III/LAV infection; and (AIDS) were ?rst described in the summer of 1981 [CDCi [0010] 2. that the Center For Disease Control (CDC) Pneumocystis pneumoniaiLos Angeles. MMWR 1981, develop more inclusive de?nitions and classi?cations of 30:250-2; CDCiKaposi ’s sarcoma and Pneumocystis pneu HTLV-III/LAV infection for diagnosis, treatment, and monia among homosexual meniNew York City and Cali 0r— prevention, as well as for epidemiologic studies and nia. MMWR 1981, 30:305-8]. A case de?nition ofAIDS for special surveys; and national reporting was ?rst published in the MMWR in Sep [0011] 3. that the following re?nements be adopted in the tember 1982 [CDC-Hepatitis B virus vaccine safety: report of case de?nition of AIDS used for national reporting: an inter-agency group MMWR 1982, 311465-67; CDCi [0012] a. In the absence of the opportunistic diseases Update on acquired immune de?ciency syndrome (AIDS) required by the current case de?nition, any of the United States. MMWR 1982, 31:507-14]. Since then the following diseases will be considered indicative of de?nition has undergone minor revisions in the list of dis AIDS if the patient has a positive serologic or viro eases used as indicators of underlying cellular immunode? logic test for HTLV-III/LAV: ciency [J affe H W, Bregman D J, Selik R M. Acquired immune [0013] 1. disseminated histoplasmosis (not con?ned to de?ciency syndrome in the United States: the ?rst 1,000 lungs or lymph nodes), diagnosed by culture, histology, cases. J Infect Dis 1983, 148:339-45; Jaffe H W, Selik R M. or antigen detection; Acquired immune de?ciency syndrome: is disseminated [0014] 2. isosporiasis, causing chronic diarrhea (over 1 aspergillosis predictive of underlying cellular immune de? month), diagnosed by histology or stool microscopy; ciency?, (Reply to letter), J Infect Dis 1984, 149;829; Selik R [0015] 3. bronchial or pulmonary candidiasis, diagnosed M, Haverkos H W, Curran J W. Acquired immune de?ciency by microscopy or by presence of characteristic white syndrome (AIDS) trends in the UnitedStates, 1978-1982,Am. plaques grossly on the bronchial mucosa (not by culture J Med 1984, 76:493-500; CDC, Update: acquired immuno alone); de?ciency syndrome (AIDS)iUnited States. MMWR 1984, [0016] 4. non-Hodgkins’ lymphoma of high-grade 32:688-91] pathologic type (diffuse, undifferentiated) and of B-cell [0006] Since the 1982 de?nition was published, human unknown immunologic phenotype, diagnosed by T-cell lymphotropic virus type III/lymphadenopathy-associ biopsy; ated virus (HTLV-III/LAV) has been recognized as the cause [0017] 5. histologically con?rmed Kaposi’s sarcoma in of AIDS, The clinical manifestations of (HTLV-III/LAV) patients who are 60 years old or older when diagnosed. infection may be directly attributable to infection with this [0018] b. In the absence of the opportunistic diseases virus or the result of secondary condtions occurring as a required by the current case de?nition, a histologi consequence of immune dysfunction caused by the underly cally con?rmed diagnosis of chronic lymphoid inter ing infection with (HTLV-III/LAV). The range of manifesta stitial pneumonitis in a child (under 13 years of age) tions may include none, nonspeci?c signs and symptoms of will be considered indicative of AIDS unless test(s) illness, autoimmune and neurologic disorders, a variety of for HTLV-III/LAV are negative. opportunistic infections, and several types of malignacy. [0019] c. Patients who have a lymphoreticular malig AIDS was de?ned for national reporting before its etiology nancy diagnosed more than 3 months after the diag was known and has encompassed only certain secondary nosis of an opportunistiic disease used as a marker for conditions that reliably re?ected the presence of a sever AIDS will no longer be excluded as AIDS cases. immune dysfunction. Current laboratory tests to detect [0020] d. To increase the speci?city of the case de? (HTLV-III/LAV) antibody make it possible to include addi nition, patients will be excluded as AIDS cases if they US 2014/0234454 A1 Aug. 21,2014 have a negative result on testing for serum antibody to plaster-like basis part is applied to the wound or swollen area HTLV-III/LAV, have no other type of HTLV-III/LAV about 0.5 cm in thickness. The wound is then bandaged and test with a positive result, and do not have a low the medicine is renewed once or twice a day until fresh ?esh number of T-helper lymphocytes or a low ratio of appears in the wound. Thereafter, the medicine is continu T-helper to T-suppressor lymphocytes. In the absence ously applied but in a dry form until the wound is completely of test results, patients satisfying all other criteria in healed. The extract medicament composition taught by Chen the de?nition will continue to be included. CDC will et al., does not have any impact on AIDS itself as a systemic immediately adopt the above amendments to the case disease. de?nition of AIDS for national reporting. [0021] This revision in the ease de?nition will result in the SUMMARY OF THE INVENTION reclassi?cation of less than 1% of cases previously reported to [0024] The present invention is related to a composition for CDC.